Dr. Mandler, molecular biologist by training, is founder and CEO of Tridem Bioscience, bringing with him over 15 years of collaborative research and management experience in academia and industry.
Dr. Mandler is the former CSO of Accanis Biotech. Prior to that he served as head of the Neurodegeneration Department at AFFiRiS AG where he was developing the vaccine portfolio for the treatment of neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and multisystem atrophy. In this position he was responsible for preclinical development of the first two peptide-based vaccines ever tested in humans for Parkinson's disease and multisystem atrophy.
He has authored 20 publications in high impact journals and more than 25 patents and patent applications and has received multiple national and international research grants for his work.
Dr. Sabine Schmidhuber principal scientist & project leader
Dr Schmidhuber is a molecular biologist by training with extensive experience in academia and the biotech industry with a particular focus on identifying new vaccine candidates and establishing methods for evaluating their efficacy.
Previously, Dr. Schmidhuber was project leader at Accanis Biotech as well as project leader for late preclinical vaccine development in the Neurodegeneration Department of AFFiRiS AG, with a particular focus on establishing new methods for evaluating preclinical and clinical efficacy of vaccines in Parkinson’s disease. She received her PhD from Paracelsus Medical Private University (Salzburg, Austria) and Kings College in London (UK) and completed her post-doctoral training at Saban Research Institute of Childrens Hospital Los Angeles and PMU Salzburg, focusing on inflammation and innate immunity.
Dr Schmidhuber is author/co-author of >15 peer-reviewed publications as well as one published and several unpublished patents/patent applications.
Rudolf Waisenhorngasse 33a/2/3
1230 - Wien